AA
SVA

Apriem Advisors’s Sinovac Biotech, Ltd SVA Stock Holding History

Apriem Advisors’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-300
Closed -$1K – 600
2014
Q3 		$1K Hold
300
– – ﹤0.01% 522
2014
Q2 		$2K Hold
300
– – ﹤0.01% 447
2014
Q1 		$2K Hold
300
– – ﹤0.01% 466
2013
Q4 		$2K Hold
300
– – ﹤0.01% 479
2013
Q3 		$2K Hold
300
– – ﹤0.01% 472
2013
Q2 		$1K Buy
+300
New +$1.12K ﹤0.01% 468

Other funds holding SVA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PRCM
Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Apriem Advisors's SVA Position: Q4 2014 in Review

Apriem Advisors sold out of Sinovac Biotech, Ltd (SVA) in Q4 2014, closing a stake of 300 shares — an estimated $1K sold.

Apriem Advisors first reported a position in SVA in Q2 2013 and held it in 6 quarters. The position peaked at $2K in Q2 2014. 43 funds tracked by Wall St. Rank hold SVA as of Q4 2014.

  • Apriem Advisors reported no remaining Sinovac Biotech, Ltd position as of Q4 2014 after selling out during the quarter.
  • Apriem Advisors sold 300 Sinovac Biotech, Ltd shares in Q4 2014, an estimated $1K.
  • Apriem Advisors first reported a position in Sinovac Biotech, Ltd in Q2 2013 and held it in 6 quarters.
  • Apriem Advisors's Sinovac Biotech, Ltd position peaked at $2K in Q2 2014.
  • 43 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q4 2014.

Based on Apriem Advisors's 13F filing for Q4 2014, filed 12 Feb 2015.